For instance, the use of BC murine models has shown that targeting the tumor vasculature with low doses of anti-VEGFR2 antibodies not only results in a homogeneous distribution of functional tumor vessels, but also facilitates tumor infiltration by CD4+ and CD8+ T cells and reverts the TAM phenotype from the pro-tumorigenic M2-like one to the antitumor, M1-like one [126]. The gene discussed is CD8A; the disease is breast cancer.